Looking to invest, acquire, license, or partner?
EVENT IN NUMBERS
attending companies developing innovative pipelines and platforms
company presentations showcasing new data, and disruptive new technologies
hours of dedicated face-to-face networking
alignment on interests and intentions
For Pharma
With representation from the key players, gather with other oncology large pharma innovation scouts and business development teams, looking to assess, qualify or understand infrastructure for due diligence on promising ADC or Radiopharmaceutical technologies, in scope and on strategy for external innovation.
Gathering oncology large pharma innovation scouts and business development teams, looking to assess, qualify, or understand due diligence on promising technologies for external innovation.
Assess disruptive science across novel linker and conjugation technologies and future payloads or radioligands, and evaluate new collaboration opportunities, earlier in development.
This face-to-face, targeted partnership opportunity is for:
- Search & Evaluation
- Licensing & Acquisitions
- Venture
- External Innovation
- Transactions
- Strategic Partnering & Pharma Partnering
Meet some of our pharma speakers:
• David Dowling, Global Search & Evaluation Lead, Oncology Strategy, Roche
• Andressa Smith, Senior Director, Scientific Licensing & Acquisition, Oncology Business Development, Johnson & Johnson
• Steve Bartz, Head of Oncology Business Development, Search & Evaluation, BMS
• Jenny Wang, Director Search & Evaluation, Oncology, AbbVie
For Biotech & Academics
Creating a platform for face-to-face networking with targeted decision makers hyper-relevant to ADC and radiopharmaceutical investment, acquisition, licensing, and partnership; understanding what’s on scope and in strategy for buyers initiating business-to-business deals.
Creating a platform for face-to-face networking with targeted investment, acquisition, licensing, and partnership decision makers, understanding buying activity and strategy to align with promising collaborators.
Validate your technologies to differentiate in a competitive market, raise capital for re-investment, and expand the list of buyers interested in your promising new science.
Enabling more face time, better exposure, greater engagement, and more opportunity for constructive meetings, for:
- Chief Executive Officers
- Head of Business Development
- Chief Scientific or Technology Officers
- Founders & Co-Founders
Join our ADC & Radiopharmaceutical company speakers:
John Flygare, Co-Founder & Chief Scientific Officer, Firefly Biologics
Neil Bander, Chief Scientific Officer, Convergent Therapeutics
Ingo Lehrke, Chief Business Officer, Tubulis
For Investors
As ADCs and Radiopharmaceuticals continue to be the most exciting opportunity for investment, deal activity, and clinical progress in life sciences, capitalize on the world’s largest gathering of business decision makers in early development to identify strategic assets with promising returns.
Filled with company presentations, strategic insights from deal-making activity, and direction into future trends, evaluate strategic assets with promising returns.
Identify attractive investment opportunities, outline your differentiated expertise, and establish a greater track record of delivering targeted capital across ADCs.
Increase the efficiency of your networking, strategic reach, and investment conversations to broaden your portfolio, by sending:
- Investment Directors
- Principals
- Partners
Join our investor speakers:
Cookie Yu, Investment Director, Samsung Venture Investment Corporation
Harris Webber, Principal, Bain Capital Life Sciences
Testimonials
I see this as a great opportunity to network with industry peers and charter new exciting paths for the recently revived ADC field
Natalia Ulyanova, Business Development Director, Oncology
This is an opportunity to meet and exchange with the whole community burning to the true potential of ADCs
Ingo Lehrke, Chief Business Officer
I hope to collaborate with my colleagues in the industry to discuss and brainstorm the best ways to bring forth the next generation of ADCs
Christopher Davies, Business Development Project Leader